Cristian Antonio Wieczorek Villas Boas (0000-0003-0048-4749)

Personal information

Biography

Currently hired as a Postdoctoral Research Associate at Washington University in St. Louis, Cristian A. W. Villas Boas assists in developing new radiopharmaceuticals for diagnosing and treating Glioma, Prostate Cancer, Lung Cancer, and Breast Cancer. Cristian A. W. Villas Boas has two years of experience in organic synthesis and six years of experience in radiolabeling peptides and proteins. Part of Cristian’s abilities is cell culture, plasmid preparation, establishing in vivo mouse tumor models, and carrying out in vitro and animal experiments, such as imaging studies (PET/CT), dosimetry, and biodistribution studies. In addition, Cristian has experience in radiolabeling with copper-64, copper-67, gallium-68, zirconium-89, yttrium-90, technetium-99m, indium-111, and lutetium-177.
Cristian was a Ph.D. fellowship at IPEN (Nuclear and Energetic Research Institute, 2017-2020). The main goal of the doctoral project was to develop the radiolabeling of [177]Lu-PSMA-617, carry out scale-up studies with therapeutic doses, and study in vitro and in vivo the effect of lutetium-177 carrier-free and non-carrier-free. Cristian is graduated in Pharmacy (Faculdade Oswaldo Cruz, 2005-2010) and has a master's degree (Universidade Anhanguera de São Paulo, 2011-2013). Also, Cristian is specialized in Business Management (SENAC, 2015-2016).
Cristian worked as a professor in the specialized course of Clinical Pharmacy at Oswaldo Cruz Faculties (2014-2015).
Cristian has experience in the field of Pharmacy, with an emphasis on organic synthesis, radiopharmacy, and molecular imaging.
Cristian was a member of the Advisory Committee on Radiopharmacy by the Regional Council of Pharmacy of the State of São Paulo, Brazil (2018-2022). Currently, Cristian is a member of the Society of Radiopharmaceutical Sciences. Since February 2023, Cristian has been the coordinator of the Postdoc Peer Mentorship Program at Washington University in St. Louis.

Activities

Collapse all

Conselho Regional de Farmácia do Estado de São Paulo: São Paulo, São Paulo, BR

2018-07 to present | Acessor (Comissão de Radiofarmácia)

Employment

Cristian Antonio Wieczorek Villas Boas

https://orcid.org/0000-0003-0048-4749

Personal information

Other IDs

Keywords

Countries

Biography

Activities

Employment (4)

Conselho Regional de Farmácia do Estado de São Paulo: São Paulo, São Paulo, BR

Erboristeria Aurea Farmácia de Manipulação: São Paulo, SP, BR

Faculdades Oswaldo Cruz: São Paulo, São Paulo, BR

RaiaDrogasil S/A: São Paulo, SP, BR

Education and qualifications (5)

Washington University in St. Louis: St Louis, Missouri, US

Universidade de Santo Amaro: Sao Paulo, SP, BR

Senac São Paulo: Sao Paulo, São Paulo, BR

Universidade Bandeirante de São Paulo: São Paulo, São Paulo, BR

Faculdades Oswaldo Cruz: São Paulo, São Paulo, BR

Professional activities (1)

Conselho Regional de Farmacia do Estado de São Paulo: São Paulo, São Paulo, BR

Funding (2)

Obtaining and evaluating the applicability in the treatment of prostate cancer of the PSMA-617 Kit for prompt radiolabeling with lutetium-177

Obtenção de Kit de PSMA-617 para pronta marcação com lutécio-177 e avaliação da sua aplicabilidade no tratamento do câncer de próstata

Works (41)

Data from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Data from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S10 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S10 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S11 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S11 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S12 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S12 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S13 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S13 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S4 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S4 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S5 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S5 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S6 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S6 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S7 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S7 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S8 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S8 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S9 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Figure S9 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Table S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Table S1 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Table S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Table S2 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Table S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

Supplementary Table S3 from Development of a [<sup>89</sup>Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library

In vitro and in vivo response of PSMA-617 radiolabeled with CA and NCA lutetium-177

Stability in the production and transport of 177Lu labelled PSMA

177Lu-PSMA-617: Brazilian Experience

Avaliação pré-clínica do potencial de inibidor do antígeno de membrana prostático específico (PSMA) radiomarcado com lutécio-177 no tratamento do câncer de próstata

Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma

Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma

Peer review (3 reviews for 2 publications/grants)